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OBJECTIVEdThe objective of this study was to determine potential added value of novel risk
factors in predicting the development of type 2 diabetes beyond that provided by standard
clinical risk factors.
RESEARCH DESIGN AND METHODSdThe Atherosclerosis Risk in Communities
(ARIC) Study is a population-based prospective cohort study in four U.S. communities. Novel
risk factors were either measured in the full cohort or in a case-control sample nested within the
cohort. We started with a basic prediction model, previously validated in ARIC, and evaluated 35
novel risk factors by adding them independently to the basic model. The area under the curve
(AUC), net reclassification index (NRI), and integrated discrimination index (IDI) were calcu-
lated to determine if each of the novel risk factors improved risk prediction.
RESULTSdThere were 1,457 incident cases of diabetes with a mean of.7.6 years of follow-
up among 12,277 participants at risk. None of the novel risk factors significantly improved the
AUC. Forced expiratory volume in 1 s was the only novel risk factor that resulted in a significant
NRI (0.54%; 95% CI: 0.33–0.86%). Adiponectin, leptin, g-glutamyl transferase, ferritin, inter-
cellular adhesion molecule 1, complement C3, white blood cell count, albumin, activated partial
thromboplastin time, factor VIII, magnesium, hip circumference, heart rate, and a genetic risk
score each significantly improved the IDI, but net changes were small.
CONCLUSIONSdEvaluation of a large panel of novel risk factors for type 2 diabetes in-
dicated only small improvements in risk prediction, which are unlikely to meaningfully alter
clinical risk reclassification or discrimination strategies.
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A number of risk prediction tools fortype 2 diabetes have been developedthat could be used for opportunistic
screening in clinical practice; however, at
this time, there is no widely accepted risk
prediction score that has been developed
and validated in routine clinical practice
(1,2). Developing a tool that successfully
identifies those at high risk of type 2
diabetes is important because the disease
is largely preventable through lifestyle and/
or pharmacologic interventions (3). There-
fore, the successful identification of at-risk
individuals, via risk prediction models,
would create greater opportunities for
clinicians to intervene to prevent or delay
the onset of type 2 diabetes and the com-
plications associated with this disease (4).
Within the last decade, a number of
potential new risk factors for type 2 di-
abetes have been identified that are re-
lated to chronic inflammation, metabolic
abnormalities, endothelial dysfunction,
oxidative stress, and a prothrombotic
state. Many of these factors have been
found to be independently associated
with type 2 diabetes in prospective cohort
studies, including the Atherosclerosis
Risk in Communities (ARIC) Study
(5–21). Likewise, a number of common
gene variants have been identified that are
associated with type 2 diabetes in both
candidate gene and genome-wide associ-
ation studies. Because there is a possibility
that one or more of these novel risk fac-
tors could serve in a tool for predicting
type 2 diabetes, allowing clinicians to in-
tervene and prevent the onset of disease, it
is important to identify those risk factors
that may refine and improve tools for risk
prediction. Therefore, the purpose of this
analysis is to identify novel risk factors
that could improve type 2 diabetes risk
prediction.
RESEARCH DESIGN
AND METHODSdThe ARIC Study
began in 1987–1989 and recruited a
population-based cohort from four U.S.
communities including: Forsyth County,
NC; Jackson, MS; the northwest suburbs
of Minneapolis, MN; and Washington
County, MD (22). Participants received
an extensive examination, including med-
ical, social, and demographic data. The
baseline examinations (visit 1) were con-
ducted between 1987 and 1989; visit 2
was held between 1990 and 1992; visit 3
between 1993 and 1995; and visit 4 was
conducted between 1996 and 1998. Of
participants still alive at the time of
follow-up visits, response rates for visits
2, 3, and 4 were 93, 86, and 81%, re-
spectively.
Case-control study
For some analyses, we used data from a
case-cohort study design previously used
to examine the role of inflammation in
the development of type 2 diabetes in
ARIC (8). Prior to sampling, the following
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individuals were excluded: 2,018 with
prevalent diabetes, 95members of minor-
ity ethnic groups with small numbers,
853 individuals who did not return to
any follow-up visit, 26 with no valid di-
abetes determination at follow-up, 7 with
restrictions on stored plasma use, 12 with
missing baseline anthropometric mea-
surements, and 2,506 in previous ARIC
case-control and case-cohort studies in-
volving cardiovascular disease for whom
stored plasma was either previously ex-
hausted or held in reserve. After exclu-
sions, the sampling frame consisted of
10,275 individuals.
Case subjects were defined as partic-
ipants who met any of the following
criteria for type 2 diabetes at one or
more follow-up visits: 1) self-reported
use of hypoglycemic medications; 2) ca-
sual serum glucose of $200 mg/dL; 3)
fasting (.8 h) serum glucose of $126
mg/dL; or 4) self-reported physician diag-
nosis of type 2 diabetes. There were 1,155
incident cases identified among the par-
ticipants in the sampling frame. Due to
budget constraints, all eligible type 2 di-
abetes cases were not selected for the
case-cohort design. Instead, a stratified
random sample of cases was selected
with oversampling of African Americans.
A subcohort was selected from all eligible
cohort members to serve as the compar-
ison group. Because risk-prediction soft-
ware could not readily accommodate
sample weights necessary for case-cohort
analysis, we excluded incident case sub-
jects who were independently selected
for the cohort random sample but not
the case sample (N = 23), resulting in a
final sample size of 529 case and 543 con-
trol subjects.
Phenotypic measurements
Prevalent diabetes at baseline was defined
as a nonfasting glucose $200 mg/dL, a
fasting glucose$126 mg/dL, self-reported
diagnosis of diabetes by a physician, or
the current use of medications. Parental
history of diabetes was defined as a re-
port of diabetes in either parent. Subjects
were asked to fast for 12 h prior to the
clinical examination. Anthropometric
measurements were taken with partici-
pants dressed in scrub suits without
shoes. Technicians measured waist girth
at the umbilical level. Blood pressure was
measured three times with the subject in
the sitting position after 5 min of rest
using a random-zero sphygmomanome-
ter, and the last two measurements were
averaged.
After informed consent, blood was
drawn from the antecubital vein of seated
participants. Serum glucose was measured
using a hexokinase/glucose-6-phosphate
dehydrogenase method. Triglycerides
were measured using an enzymatic
method and HDL cholesterol (HDL-C)
was measured enzymatically after dex-
tran sulfate-Mg2+ precipitation of other
lipoproteins.
Details regarding the measurement of
novel risk factors are found in Supple-
mentary Table 1.
Genotyping
Genotyping, quality control, and impu-
tation procedures for the ARIC genome-
wide association study have previously
been described (23). The genetic risk
score was created by adding together the
number of genotyped or imputed risk al-
leles of 30 genes or regions, thus assum-
ing an additive model of inheritance. The
selection of genetic variants was based
on a recent large-scale association analysis
of European Americans that combined
genome-wide association data from mul-
tiple studies to identify genetic variants
associated with type 2 diabetes (24).
The risk alleles modeled were those
used in Voight et al. (24), which indexed
alleles to the forward strand of National
Center for Biotechnology Information
Build 36. Because most of the variants
were discovered and validated in Cauca-
sian populations, the genetic risk score
was created only for Caucasian study par-
ticipants.
Statistical methods
Total cohort. Baseline characteristics of
the study population were examined by
incident type 2 diabetes status and shown
as means6 SD orN (%) and compared by
t or x2 tests. For prediction analyses, we
started with a simple or basic prediction
model, previously validated in ARIC (25),
that includes age, parental history of di-
abetes, race/ethnicity, fasting glucose,
fasting triglycerides, systolic blood
Table 1dBaseline characteristics (mean or percentage) of the total ARIC cohort by
incident type 2 diabetes status
Type 2 diabetes
(N = 1,457)
No type 2 diabetes
(N = 10,820) P value
Basic risk factors
Age (years) 54.1 53.9 0.30
Parental history of diabetes (%) 33.9 21.3 ,0.0001
Race (African American, %) 32.3 20.1 ,0.0001
Systolic blood pressure (mmHg) 125.5 118.8 ,0.0001
Waist circumference (cm) 104.6 94.5 ,0.0001
Height (cm) 169.1 168.4 0.006
Fasting triglycerides (mg/dL) 155.1 120.5 ,0.0001
HDL-C (mg/dL) 45.8 53.4 ,0.0001
Fasting glucose (mg/dL) 108.1 97.3 ,0.0001
Novel risk factors
WBC count (1,000/mm3) 6.4 6.0 ,0.0001
Fibrinogen (mg/dL) 310.0 296.7 ,0.0001
Albumin (g/dL) 3.9 3.8 0.22
vWF (%) 120.3 113.5 ,0.0001
aPTT (s) 29.0 29.3 ,0.0001
Factor VIII (%) 135.1 126.1 ,0.0001
Magnesium (mg/dL) 1.63 1.65 ,0.0001
FEV1 (L) 2.8 2.9 ,0.0001
FVC (L) 3.7 3.9 ,0.0001
Hematocrit (%) 42.4 41.5 ,0.0001
Heart rate (bpm) 67.0 65.4 ,0.0001
Low-frequency-power heart
rate variability (ms) 23.9 23.4 0.34
Leg length (cm) 80.1 79.6 0.0005
Hip circumference (cm) 109.0 103.3 ,0.0001
Blood viscosity (centipoise) 6.0 5.9 0.001
Genetic risk score (number of risk alleles)* 29.1 29.8 ,0.0001
*Genetic risk score was available only in Caucasian participants.
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pressure, HDL-C, height, and waist cir-
cumference, all measured at visit 1. The
expanded model for the full cohort con-
sidered the following measures obtained
at visit 1 and reported to be associated
with incident type 2 diabetes in previous
ARIC publications:
c White blood cell (WBC) count
c Fibrinogen
c Albumin
c von Willebrand factor (vWF) antigen
c Activated partial thromboplastin time
(aPTT)
c Factor VIII coagulant activity
c Serum magnesium
c Forced vital capacity (FVC)
c Forced expiratory volume in 1 s (FEV1)





c Low frequency power heart rate vari-
ability
c Genetic risk score that includes variants
from the following 30 genes or regions:
NOTCH2 (rs10923931), THADA (rs-
7578597), BCL11A (rs243021), PPARG
(rs1801282), ADAMTS9 (rs6795735),
IGF2BP2 (rs1470579), WFS1 (rs-
10010131), ZBED3 (rs4457053),
CDKAL1 (rs7754840), JAZF1 (rs-





TCF7L2 (rs7903146), KCNQ1 (rs-




PRC1 (rs8042680), FTO (rs9939609),
HNF1B (rs75210),MTNRB1 (rs1387153),
and IRS1 (rs7578326)
We used Cox proportional hazards
regression models, with incident type 2
diabetes as the outcome, to calculate the C
statistic for each individual risk factor.We
defined incident type 2 diabetes as de-
scribed above. The date of type 2 diabetes
incidence was estimated by linear inter-
polation using glucose values at the as-
certaining visit and the previous one (8).
We constructed models by adding each
novel risk factor one at a time to the basic
risk prediction model. C statistics were
compared between the baseline model
and the model with the novel risk factor,
and if the variable produced an incremen-
tal change of at least 0.005, it was in-
cluded in the final model (25).
We used the macro derived by
Chambless et al. (26) to calculate the area
under the curve (AUC), net reclassification
index (NRI), and integrated discrimination
index (IDI) for our risk-prediction models.
The AUC is calculated via a nonparametric
method, which produces the AUC at time t
in a setting of risk prediction from sur-
vival analysis and takes censoring into
consideration (26). All analyses were
conducted using SAS version 9.2 (SAS
Institute, Cary, NC).
We excluded 2,018 individuals who
had prevalent type 2 diabetes at baseline,
95 individuals from underrepresented
minority groups, 314 individuals with
missing information on the risk factors
included in the basic risk model, 267
individuals who did not fast for at least 8
h, and 821 individuals who had no
follow-up time data to ascertain type 2
diabetes, thus leaving 12,277 individuals
for the analysis. Because the genetic risk
score was created only for Caucasian study
participants, there were 8,067 individuals
available for the analysis of the addition of a
genetic risk score to the basic model.
Case-control study
We started with the same aforementioned
basic risk-prediction model (25). The ex-
panded model for the case-control sub-
sample considered the following novel





c g-Glutamyl transferase (GGT)
c Alanine aminotransferase
Table 2dMeasures of risk prediction for the total cohort
N C statistic 95% CI* Difference NRI 95% CI* IDI 95% CI*
Basic** 12,277 0.8411 0.8316–0.8457
WBC count 12,277 0.8430 0.8429–0.8520 0.0019 0.0015 20.0036 to 0.0142 0.0043 0.0019–0.0068
Fibrinogen 12,232 0.8415 0.8396–0.8471 0.0004 20.0011 20.0004 to 0.0048 0.0003 20.0001 to 0.0011
Albumin 12,277 0.8409 0.8318–0.8456 20.0002 20.0011 20.0037 to 0.0122 0.0002 0.0001–0.0013
vWF 12,235 0.8415 0.8364–0.8450 0.0004 0.0022 20.0029 to 0.0035 0.0000 20.0000 to 0.0004
aPTT 12,226 0.8415 0.8413–0.8485 0.0004 0.0022 20.0016 to 0.0082 0.0001 0.0000–0.0011
Factor VIII 12,229 0.8418 0.8387–0.8483 0.0007 0.0016 20.0036 to 0.0109 0.0009 0.0008–0.0025
Magnesium 12,277 0.8409 0.8404–0.8474 20.0002 20.0010 20.0050 to 0.0011 0.0002 0.0000–0.0007
FEV1 11,095 0.8426 0.8419–0.8559 0.0015 0.0054 0.003320.0086 0.0001 20.0006 to 0.0018
FVC 11,095 0.8427 0.8349–0.8451 0.0016 0.0042 20.0146 to 0.0081 0.0002 20.0005 to 0.0008
Hematocrit 12,088 0.8414 0.8283–0.8560 0.0003 0.0033 20.0060 to 0.0039 0.0000 20.0000 to 0.0010
Heart rate 11,702 0.8427 0.8347–0.8490 0.0016 0.0015 20.0001 to 0.0080 0.0006 0.0005–0.0014
Low-frequency-power
heart rate variability 11,702 0.8424 0.8389–0.8450 0.0013 20.0017 20.0025 to 0.0018 20.0001 20.0000 to 0.0001
Leg length 12,274 0.8412 0.8400–0.8509 0.0001 0.0025 20.0010 to 0.0024 0.0001 20.0001 to 0.0002
Hip circumference 12,277 0.8422 0.8332–0.8514 0.0011 20.0013 20.0059 to 0.0072 0.0019 0.0009–0.0027
Blood viscosity 12,088 0.8413 0.8380–0.8449 0.0002 0.0034 20.0015 to 0.0108 20.0000 20.0000 to 0.0001
Genetic risk score*** 8,067 0.8496 0.8385–0.8604 0.0012 20.0032 20.0130 to 0.0108 0.0018 0.0011–0.0024
The basic model was rerun for each covariate, and the difference between the basic and expanded models was calculated accordingly due to changing sample sizes.
*The 95% CIs were bootstrapped. **The basic model includes age, parental history of diabetes, race/ethnicity, fasting glucose, fasting triglycerides, systolic blood
pressure, HDL-C, height, and waist circumference. ***Modeled only in Caucasians.
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c Asymmetric dimethylarginine (ADMA)
c Retinol binding protein 4 (RBP-4)
c Free fatty acids
c Oxidized LDL
c Lactate
For the case-control analysis, we used
logistic regression models, with incident
type 2 diabetes as the outcome, to calcu-
late the C statistics for each individual risk
factor. We constructed models by adding
each novel risk factor independently to
the basic risk-prediction model, as we did
in the total cohort, and looked for an
incremental change of at least 0.005. We
used the nriidi macro created by Sundstrom




There were 1,457 (11.9%) incident cases
of type 2 diabetes with a mean of .7.6
years of follow-up. Unadjusted baseline
characteristics of the type 2 diabetes and
non–type 2 diabetes groups for the total
cohort are summarized in Table 1. Indi-
viduals with incident type 2 diabetes were
more likely to have a parental history of
diabetes, be African American versus
white, have a higher systolic blood pres-
sure, higher mean waist circumference,
greater mean height, higher levels of fast-
ing triglycerides and glucose, and lower
levels of HDL-C. In terms of novel risk
factors, individuals with incident type 2
diabetes had statistically significantly dif-
ferent levels of all novel risk factors except
albumin and low-frequency-power heart
rate variability when compared with
those without incident type 2 diabetes.
Multivariate-adjusted hazard rate ra-
tios for the variables included in the basic
risk model are shown in Supplementary
Table 2. Supplementary Table 3 shows
the correlations between novel and basic
risk factors. All of the novel risk factors
except for the genetic risk score were sig-
nificantly correlated with at least three of
the six basic risk factors, and the majority
of novel risk factors are significantly
correlated with five or more basic risk fac-
tors. However, it is important to note that
not all of these correlations were strong. By
contrast, the genetic risk score was only
correlated with baseline glucose levels.
The basic model had an AUC of
0.8411 (95% CI: 0.8316–0.8457) (Table
2). There were no novel risk factors that
improved the AUC of the basic model by
an increment of at least 0.005. All of the
novel risk factors, with the exception of
FEV1, did not have statistically significant
NRIs. The NRI when adding FEV1 to the
basic model was 0.54% (95% CI: 0.33–
0.86%). Finally, the addition of WBC
count, albumin, aPTT, factor VIII, mag-
nesium, heart rate, hip circumference, or
the genetic risk score statistically signifi-
cantly increased the IDI.
Nested case-control sample
Baseline characteristics of incident type 2
diabetes case and control subjects in the
nested case-control subsample are sum-
marized in Table 3. All novel risk factors
were statistically significantly different
between case and control subjects. Sup-
plementary Table 4 shows that all of the
novel risk factors were significantly corre-
lated with at least two of the basic risk
factors, and the majority of novel risk fac-
tors were significantly correlated with
three or more basic risk factors. As with
the total cohort, not all of these risk fac-
tors were strongly correlated.
The basic model, which included the
aforementioned risk factors from the
Schmidt et al. (25) analysis, had an AUC
of 0.8607 (95% CI: 0.8386–0.8828) (Ta-
ble 4). None of the novel risk factors im-
proved the C statistic by at least 0.005. In
terms of model fit, the addition of ICAM-1
had the greatest improvement as it came
closest to achieving the 0.005 increment
of change in the AUC. None of the novel
risk factors exhibited a statistically
Table 3dBaseline characteristics (mean or percentage) of case-control sample by
type 2 diabetes status
Type 2 diabetes
(N = 522)
No type 2 diabetes
(N = 526) P value
Basic risk factors
Age (years) 53.1 52.3 0.03
Parental history of diabetes (%) 35.3 22.2 ,0.0001
Race (African American, %) 47.9 41.1 0.03
Systolic blood pressure (mmHg) 124.8 119.2 ,0.0001
Waist girth (cm) 105.0 94.0 ,0.0001
Height (cm) 167.8 167.3 0.39
Triglycerides (mg/dL) 146.1 108.6 ,0.0001
HDL-C (mg/dL) 47.9 56.3 ,0.0001
Glucose (mg/dL) 108.1 96.7 ,0.0001
Novel risk factors
Adiponectin (mg/mL) 6.9 9.3 ,0.0001
High-molecular-weight adiponectin (g/mL) 1.9 3.0 ,0.0001
Leptin (ng/mL) 26.1 19.4 ,0.0001
GGT (U/L) 21.0 15.9 0.002
Alanine aminotransferase (U/L) 14.7 12.6 0.01
Fetuin A (g/mL) 501.5 486.5 0.009
Ferritin (ng/mL) 202.9 144.4 ,0.0001
C-reactive protein (mg/mL) 3.8 2.7 ,0.0001
Lactate (mg/dL) 9.4 8.3 ,0.0001
Oxidized LDL (U/L) 42.7 38.9 ,0.0001
ICAM-1 (ng/mL) 277.3 255.8 ,0.0001
Orosomucoid (mg/dL) 94.6 86.6 ,0.0001
Sialic acid (mg/dL) 100.8 93.5 ,0.0001
Interleukin-6 (pg/mL) 3.3 2.7 0.003
Interleukin-18 (pg/mL) 254.0 234.4 0.01
Complement C3 (mg/dL) 173.2 151.8 ,0.0001
RBP-4 (mg/mL) 31.2 29.3 0.0002
Nonesterified free fatty acids (g/L) 0.9 0.8 0.0009
ADMA (mmol/L) 0.25 0.24 0.04
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significant NRI. ADMA, interleukin-18,
GGT, and lactate exhibited no movement
between risk categories, and therefore, an
NRI calculation was not made. Adiponec-
tin, leptin, GGT, ferritin, ICAM-1, and
complement C3 had statistically signifi-
cantly improved IDIs.
CONCLUSIONSdNone of the novel
risk factors significantly improved the AUC
in the total cohort or nested case-control
sample. However, FEV1 did significantly,
albeit modestly, improve the NRI in the
total cohort. None of the risk factors statis-
tically significantly improved theNRI in the
case-control study sample; however, the
addition of adiponectin, leptin, GGT, ferri-
tin, ICAM-1, and complement C3 did sta-
tistically significantly but moderately
improve the IDI. Likewise, in the total co-
hort, the novel risk factors WBC count, al-
bumin, aPTT, factor VIII, magnesium,
heart rate, hip circumference, and the ge-
netic risk score exhibited significant but
modest improvements in IDI. These results
suggest that of these novel risk factors, only
FEV1maybehelpful for type 2diabetes risk
stratification in theARIC cohort study. Sev-
eral novel risk factors did modestly im-
prove the IDI, which indicates that the
difference in average predicted probabili-
ties between individuals with and without
type 2 diabetes significantly increased
when these risk factors were added to the
basicmodel; however, critics argue that it is
unclear whether a significant IDI indicates
that the novel risk factor in the model is
clinically useful (28,29).
Despite the fact that many of the
novel risk factors are independent risk
factors for type 2 diabetes in the total
cohort, none of these risk factors ap-
peared to provide additional value to
type 2 diabetes risk prediction. Previous
studies that have incorporated one or
more novel risk factors into a risk pre-
diction model have been limited, and
although these analyses may have found
increased AUCs with the inclusion of
novel risk factors, they are also often
single studies in very specific populations
(4,30,31). Our own study failed to repli-
cate the contributions of WBC count,
heart rate, or alanine aminotransferase to
the improvement in the AUC, as found in
the aforementioned studies (4,30,31). It
is important to note that although novel
risk factors may be associated with type 2
diabetes, it does not mean they will con-
tribute to risk prediction, as these are
separate issues of etiology and prediction
(32). All of the novel risk factors modeled
in the total cohort and case-control anal-
yses were significantly associated with
type 2 diabetes in ARIC; however, none
of them significantly contributed to im-
proved risk prediction when C statistics
were calculated with and without the
novel risk factors.
It is difficult to improve upon existing
risk factors for type 2 diabetes. Specifi-
cally, when a single measurement of
obesity or glycemia is included in a risk
model, the AUCs already range from
0.66–0.77. When obesity and glycemia
measures are combined with readily avail-
able clinical variables, such as those in-
cluded in the basic model, the AUC
increases greatly, making it difficult to im-
prove the risk prediction (32). Further-
more, the correlation between novel risk
factors and traditional risk factors must
also be considered, as correlated risk fac-
tors provide less independent informa-
tion about type 2 diabetes risk. We
found this to be true in our own analysis,
as many statistically significant correla-
tions existed between traditional risk fac-
tors and novel risk factors in both the total
cohort and the case-control analysis.
Table 4dMeasures of risk prediction and model fit for the case-control sample
N C statistic 95% CI Difference* AIC NRI (SE) P value IDI (SE) P value
Basic** 1,048 0.8607 0.8386–0.8828 979
Adiponectin 1,048 0.8624 0.8404–0.8844 0.0017 996 0.0133 (0.0083) 0.11 0.0034 (0.0017) 0.04
High-molecular-weight
adiponectin 1,043 0.8604 0.8382–0.8827 0.0002 997 0.0019 (0.0051) 0.71 0.0002 (0.0005) 0.70
Leptin 1,048 0.8617 0.8396–0.8838 0.0010 976 0.0076 (0.0060) 0.21 0.0031 (0.0015) 0.04
GGT 1,046 0.8613 0.8392–0.8834 0.0004 973 0.0000 (0.0054) 1.00 0.0038 (0.0019) 0.04
Alanine
aminotransferase 1,046 0.8607 0.8385–0.8828 20.0002 976 20.0019 (0.0042) 0.66 0.0015 (0.0013) 0.25
Fetuin A 1,038 0.8614 0.8393–0.8836 0.0005 966 20.0019 (0.0051) 0.70 0.0022 (0.0014) 0.10
Ferritin 1,017 0.8644 0.8423–0.8865 0.0020 937 0.0019 (0.0065) 0.77 0.0051 (0.0023) 0.03
C-reactive protein 1,048 0.8610 0.8389–0.8831 0.0003 978 0.0057 (0.0042) 0.18 0.0006 (0.0008) 0.50
Lactate 1,030 0.8613 0.8391–0.8836 0.0001 960 0.0000 (0.0027) 1.00 0.0001 (0.0020) 0.70
Oxidized LDL 1,048 0.8608 0.8386–0.8829 0.0001 979 0.0038 (0.0026) 0.16 0.0002 (0.0041) 0.56
ICAM-1 1,024 0.8644 0.8423–0.8865 0.0028 947 0.0078 (0.0067) 0.24 0.0062 (0.0023) 0.01
Orosomucoid 1,048 0.8613 0.8392–0.8833 0.0006 978 0.0076 (0.0047) 0.10 0.0006 (0.0008) 0.40
Sialic acid 1,048 0.8608 0.8387–0.8830 0.0001 979 20.00001 (0.0038) 0.99 0.0004 (0.0006) 0.43
Interleukin-6 1,048 0.8611 0.8390–0.8832 0.0004 978 0.0076 (0.0038) 0.05 0.0006 (0.0007) 0.41
Interleukin-18 1,037 0.8621 0.8399–0.8842 0.0000 965 0.0000 (0.0000) d 0.0000 (0.0001) 0.69
Complement C3 1,043 0.8623 0.8402–0.8844 0.002 970 0.0037 (0.0076) 0.62 0.0044 (0.0019) 0.02
RBP-4 1,038 0.8612 0.8390–0.8833 0.0003 968 20.0058 (0.0051) 0.26 0.0030 (0.0006) 0.63
Nonesterified free fatty
acids 1,047 0.8614 0.8393–0.8835 0.0010 975 0.0019 (0.0069) 0.78 0.0027 (0.0016) 0.09
ADMA 1,033 0.8585 0.8361–0.8810 0.0000 971 0.0000 (0.0000) d 20.0000 (0.0002) 0.97
*The basic model was rerun for each covariate, and the difference between the basic and expanded models was calculated accordingly due to changing sample sizes.
**The basic model includes age, parental history of diabetes, race/ethnicity, fasting glucose, fasting triglycerides, systolic blood pressure, HDL-C, height, and waist
circumference.
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Recent advances in the identification
of a number of genetic variants associated
with type 2 diabetes have generated in-
terest in the clinical utility of combining
the loci associated with type 2 diabetes
into a genetic risk score, which could be
used for risk prediction. Thus far, the use
of genetic risk scores in type 2 diabetes
risk prediction models prior to this anal-
ysis has been limited, often involved a
smaller number of genetic variants, and
yielded varied results (33).
Our own analysis did not find a sta-
tistically significant contribution to the
AUC or NRI with the addition of a genetic
risk score; however, it did moderately
improve the IDI. The incorporation of a
genetic risk score into future type 2 di-
abetes risk prediction models could be
more useful, once an ideal set of variants is
identified, as genes are not prone to the
biological variability or measurement er-
ror that often accompanies other risk
factors. Further, the genotype does not
change over one’s lifetime, and this offers
opportunities for earlier screening and
identification of individuals at risk (34).
In fact, de Miguel-Yanes et al. (35) found
that the incorporation of a genetic score
into a risk model was actually more ben-
eficial in younger subjects. Identifying in-
dividuals at risk earlier in the disease
process will allow for interventions that
can either reverse the course of the disease
or control its accompanying risk factors
such as dyslipidemia and hypertension.
Limitations to this study include the
absence of an oral glucose tolerance test or
hemoglobin A1c test results to classify
type 2 diabetes and the use of a single
baseline value for the novel risk factors,
which does not capture the variation in
levels over time for risk factors. Further,
not all novel risk factors are included in
this analysis. We chose to only include
biomarkers that had not previously been
included in risk prediction analyses in
ARIC and biomarkers that were measured
and not self-reported.
Another limitation is the inclusion of
only 30 SNPs in the genetic risk score,
which account for only a small fraction of
the heritability of type 2 diabetes (36). Fi-
nally, there were 35 novel risk factors eval-
uated, resulting inmultiple testing thatmay
yield false positives. A strength of this anal-
ysis was the availability of a large, popula-
tion-based cohort of white and African
American men and women with follow-
up data. Further, there were standardized
data collectionmethods for both predictors
and type 2 diabetes outcomes.
In conclusion, ourmodeling indicates
that no novel risk factor contributed
significantly to risk prediction, as mea-
sured by the AUC. There was a modest
improvement in risk classification with
the addition of FEV1 and a small improve-
ment in the IDI with the addition of WBC
count, aPTT, albumin, factor VIII, magne-
sium, heart rate, hip circumference, and
the genetic risk score in the total cohort
and adiponectin, leptin, GGT, ferritin,
ICAM-1, and complement C3 in the
case-control sample. However, these
improvements are small and unlikely
to motivate refinement of clinical risk
reclassification or discrimination strat-
egies. Further study by prospective,
population-based cohort studies is
needed to confirm the generalizability of
these findings.
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